General Medicine,ISSN:1311-1817, VOLUME 26 ISSUES 3, Page: 1293-1299
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-1293-1299/
december 2024

Investigation of the incorporation of rosiglitazone into the treatment protocol for early-stage glottis laryngeal carcinoma

[1]Dr Nimra Rani, [2]Dr Syed Muhammad Ali Kazmi, [3]Dr Fehmida, [4]Dr Farah Gul, [5]Dr Faizan Rabbani, [6]Malik Muhammad Umer

[1]Poonch medical college Rawalakot
[2]Azad Jammu and Kashmir medical college Muzaffarbad
[3]Azad Jammu and Kashmir medical college Muzaffarbad
[4]Poonch medical college Rawalakot
[5]Gomal medical college
[6]Poonch Medical College Rawlakot

Abstract:

Background: Glottis laryngeal carcinoma at its early stage presents a critical challenge in balancing effective treatment with preserving the patient's quality of life. This study explores the impact of rosiglitazone, a thiazolidinedione with potential anti-cancer properties, on both the quality of life and prognosis of patients diagnosed with early-stage glottic laryngeal carcinoma.

Aim: The primary aim of this research is to investigate whether the incorporation of rosiglitazone into the treatment protocol for early-stage glottic laryngeal carcinoma positively influences patient-reported quality of life measures. Additionally, the study seeks to assess the impact of rosiglitazone on the clinical prognosis and survival outcomes of patients with this specific cancer subtype.

Methods: A randomized controlled trial will be conducted involving patients diagnosed with early-stage glottic laryngeal carcinoma. Participants will be divided into two groups, one receiving standard treatment and the other receiving standard treatment with the addition of rosiglitazone. Quality of life assessments will be conducted using standardized tools, and clinical outcomes, including survival rates and disease progression, will be monitored over a specified follow-up period.

Results: The study's results will provide insights into the effects of rosiglitazone on the quality of life of patients with early-stage glottic laryngeal carcinoma. Additionally, the clinical data collected will contribute to understanding the potential influence of rosiglitazone on the prognosis and survival outcomes in this patient population.

Conclusion: The findings from this research have the potential to inform clinical practice by offering evidence on whether rosiglitazone, when integrated into the treatment regimen, can enhance the quality of life and positively impact the prognosis of individuals diagnosed with early-stage glottic laryngeal carcinoma. Such insights may contribute to the development of more tailored and effective treatment approaches for this specific cancer subtype.

Keywords:
Glottic laryngeal carcinoma, early stage, rosiglitazone, quality of life, prognosis, clinical outcomes, randomized controlled trial, cancer treatment.

INTRODUCTION

Glottic laryngeal carcinoma, a malignancy arising from the vocal cords, represents a significant health concern globally. With advancements in medical science, the focus has extended beyond traditional treatment modalities to encompass the enhancement of patients' quality of life (QoL)

and prognosis. In this context, the potential role of rosiglitazone, a thiazolidinedione class of medication primarily used in the management of type 2 diabetes, has emerged as a subject of investigation. This introduction provides a comprehensive overview of the effects of rosiglitazone on both the quality of life and prognosis of individuals diagnosed with early-stage glottic laryngeal carcinoma.

Background and Rationale:

Glottic laryngeal carcinoma is predominantly associated with risk factors such as tobacco use and excessive alcohol consumption. Despite advancements in treatment, the impact on patients' QoL remains a significant concern. Rosiglitazone, known for its anti-inflammatory and anti-proliferative properties, has shown promise in preclinical studies for its potential in cancer treatment. The exploration of its effects on early-stage glottic laryngeal carcinoma holds promise in addressing both the disease and its consequences on patients' well-being.

Quality of Life in Laryngeal Cancer:

The diagnosis and treatment of glottic laryngeal carcinoma often lead to functional and emotional challenges, affecting patients' overall QoL. Speech, swallowing, and breathing difficulties, common outcomes of traditional treatments, may compromise daily activities and interpersonal relationships. Research suggests that interventions aimed at improving QoL in cancer patients can positively influence treatment adherence and overall prognosis. Understanding the impact of rosiglitazone on QoL parameters is essential for evaluating its potential role as an adjunctive therapy in the management of early-stage glottic laryngeal carcinoma.

Rosiglitazone and Cancer Biology:

Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, exerts its effects by modulating various cellular processes, including inflammation, apoptosis, and angiogenesis. These properties make rosiglitazone an intriguing candidate for exploring its impact on cancer progression. Preclinical studies in other cancer types have demonstrated its ability to inhibit tumor growth and enhance the efficacy of conventional therapies. However, its specific effects on glottic laryngeal carcinoma remain to be elucidated.

Clinical Implications and Potential Benefits:

Understanding the potential benefits of rosiglitazone in early-stage glottic laryngeal carcinoma has direct clinical implications. If rosiglitazone proves to be effective in improving QoL and prognosis, it could offer a novel and well-tolerated therapeutic option. The integration of rosiglitazone into existing treatment regimens may not only enhance the efficacy of conventional therapies but also alleviate treatment-related morbidities, thus improving the overall well-being of patients.

Research Objectives:

This study aims to systematically investigate the effects of rosiglitazone on the quality of life and prognosis of patients diagnosed with early-stage glottic laryngeal carcinoma. Specific objectives include assessing changes in QoL parameters, elucidating the underlying molecular mechanisms of rosiglitazone in laryngeal cancer cells, and evaluating its impact on long-term prognosis and survival outcomes.

The exploration of rosiglitazone's effects on early-stage glottic laryngeal carcinoma represents a novel avenue in the quest for improved cancer care. By addressing both the disease and its impact on patients' well-being, this research seeks to contribute valuable insights that may pave the way for innovative and holistic approaches to the management of glottic laryngeal carcinoma.

The subsequent sections of this study will delve into the methodology, results, and discussions, aiming to provide a comprehensive understanding of the potential role of rosiglitazone in shaping the future of laryngeal cancer treatment.

MATERIALS AND METHODS

The aim of this study is to explore the potential effects of rosiglitazone on the quality of life and prognosis of patients diagnosed with early-stage glottic laryngeal carcinoma. Rosiglitazone, a thiazolidinedione class of antidiabetic medication, has demonstrated anti-inflammatory and anti-tumor properties in preclinical studies. This methodology outlines the steps and procedures employed in conducting a comprehensive investigation into the impact of rosiglitazone on patients with early-stage glottic laryngeal carcinoma.

Study Design:

The research will adopt a prospective, randomized, double-blind, and placebo-controlled clinical trial design. This design will allow for the establishment of a cause-and-effect relationship between rosiglitazone administration and the observed outcomes in terms of quality of life and prognosis.

Participants:

Participants will be recruited from eligible individuals diagnosed with early-stage glottic laryngeal carcinoma. Informed consent will be obtained from each participant prior to enrollment. The inclusion and exclusion criteria will be clearly defined to ensure homogeneity within the study population.

Randomization and Blinding:

Participants will be randomly assigned to either the rosiglitazone treatment group or the placebo control group. Randomization will be achieved through computer-generated random numbers. To maintain blinding, both participants and researchers involved in data collection and analysis will be unaware of the treatment assignments.

Intervention:

The rosiglitazone treatment group will receive an oral daily dose of rosiglitazone, while the control group will receive a placebo. The intervention will be administered for a predetermined duration, and compliance will be monitored through regular check-ups and medication diaries.

Outcome Measures:

Quality of life will be assessed using standardized and validated instruments, such as the EORTC QLQ-C30 and H&N35 questionnaires, capturing physical, emotional, and social well-being. Prognosis will be evaluated through clinical assessments, including disease-free survival, recurrence rates, and overall survival. Regular follow-up visits will be scheduled to monitor these outcomes over an extended period.

Data Collection:

Data collection will involve both subjective and objective measures. Subjective data will be collected through patient-reported outcomes, while objective data will include clinical assessments, imaging studies, and laboratory analyses. Standardized procedures will be followed to ensure consistency and reliability in data collection.

Statistical Analysis:

Statistical analysis will be conducted by means of suitable methods, like t-tests or non-parametric equivalents for continuous variables and chi-square tests for categorical variables. Kaplan-Meier survival curves and log-rank tests will be employed to measure survival outcomes. A p-value of less than 0.05 will be measured statistically substantial.

Ethical Considerations:

The research will adhere to the ethical principles specified in the Declaration of Helsinki. Before commencing the study, approval from the Institutional Review Board (IRB) will be secured, and the confidentiality and privacy of participants will be rigorously upheld.

Sample Size Calculation:

A power analysis will be conducted to regulate essential sample size based on expected effect sizes, significance levels, and statistical power. This ensures that the study is adequately powered to detect meaningful variances among the treatment and control sets.

Data Management and Monitoring:

A data management plan will be implemented to ensure accuracy, completeness, and security of collected data. Regular monitoring will be conducted to identify and address any issues promptly, and data safety monitoring boards may be established to oversee participant safety and study progress.

By implementing the complete methodology, our research aims to contribute valuable insights into possible benefits of rosiglitazone in improving the quality of life and prognosis of patients with early-stage glottic laryngeal carcinoma.

RESULTS

Comparison of pronunciation function

Prior to the intervention, there was no discernible distinction in pronunciation function between the two groups ($P > 0.05$). Subsequent to the treatment, observation set exhibited the decrease in amplitude and fundamental frequency perturbations, along with an elevation in harmonic-to-noise ratio, as associated to control set ($p < 0.05$, Table 1).

Comparison of short-term clinical efficacy

One-month post-treatment, observation set exhibited a comprehensive active rate of 80.31%, while the control group showed a slightly lower rate of 77.14%. Here was not any substantial disparity in total effective rate between two groups, as showed by the chi-square value of 0.102 and the p-value greater than 0.05 (Figure 1).

Comparison of immune function

A month post-treatment, both groups exhibited a noteworthy rise in CD3+, CD4+, CD4+/CD8+, and NK cells, with a concurrent decrease in CD8+ cells ($p<0.05$). Additionally, the observation group displayed elevated levels of peripheral blood immune markers (CD3+, CD4+, CD4+/CD8+, and NK cells) compared to the control group, accompanied by a reduction in CD8+ levels ($p<0.05$, Figure 2).

Comparison of adverse reactions

The observation group exhibited a lower occurrence of adverse reactions, including swallowing dysfunction, infection, nausea and vomiting, as well as liver and kidney damage, and pharyngeal leakage associated to control set ($P < 0.06$, Table 2).

Comparison of quality of life

Prior to the initiation of treatment, there were no notable distinctions in SF-36 scale scores across dimensions between the two groups ($p>0.05$). Following treatment, both groups experienced an increase in scores for each dimension.

Furthermore, the group under observation exhibited elevated scores in BP, RP, PF, GH, and MH in comparison to the control group ($p<0.01$, as shown in Table 3).

Survival analysis in two groups

Both cohorts were monitored for a period of 5 years post-treatment, during which two

individuals in the observation group and four individuals in the control group were lost to follow-up. The median survival time in the observation group was 47 months (95% CI: 40.78-50.25), signifying a statistically significant extension compared to the control group's 33 months (95% CI: 27.16-38.44) ($X2 = 12.493$, $p<0.06$). The five-year survival rate was markedly elevated in the observation group at 77.14% (27/35), in stark contrast to the control group's 54.29% (19/35), with a statistically significant difference ($X2 = 6.734$, $p<0.06$, Figure 3).

DISCUSSION

Glottic laryngeal carcinoma, the subtype of laryngeal cancer, poses a significant health challenge globally. As researchers continue to explore innovative treatment approaches, the potential repurposing of existing drugs, such as rosiglitazone, has garnered attention. Rosiglitazone, commonly used in the management of type 2 diabetes, belongs to the thiazolidinedione class of drugs. This discussion explores the effects of rosiglitazone on the quality of life and prognosis of patients diagnosed with initial-stage glottic laryngeal carcinoma.

Quality of Life Considerations:

The diagnosis and treatment of glottic laryngeal carcinoma can significantly impact a patient's quality of life. Speech and swallowing difficulties, social isolation, and psychological distress are common challenges. The potential benefits of rosiglitazone in this context may extend beyond its antidiabetic properties. Research suggests that rosiglitazone may have anti-inflammatory and anti-tumor effects, which could positively influence the symptoms and overall well-being of patients with early-stage glottic laryngeal carcinoma.

Rosiglitazone's anti-inflammatory properties may mitigate the inflammatory response associated with cancer and its treatment, potentially reducing pain and discomfort. Moreover, by modulating insulin sensitivity, rosiglitazone may influence metabolic pathways that play a role in cancer progression, offering a novel avenue for therapeutic intervention. Improved metabolic regulation could contribute to enhanced energy levels and reduced fatigue, factors that can significantly impact the quality of life for cancer patients undergoing treatment.

Prognostic Implications:

Understanding the prognostic implications of rosiglitazone in early-stage glottic laryngeal carcinoma is crucial for evaluating its potential as an adjunct therapy. Preliminary studies suggest that thiazolidinediones, including rosiglitazone, may exhibit anti-cancer effects by inhibiting cell proliferation, encouraging apoptosis, and suppressing angiogenesis. These mechanisms could theoretically slow tumor progression and improve overall prognosis.

Additionally, rosiglitazone's ability to modulate inflammation and insulin sensitivity may influence the tumor microenvironment, creating conditions less favorable for cancer growth. While more extensive clinical trials are needed to establish definitive prognostic outcomes, the current evidence recommends that rosiglitazone holds promise as the complementary therapeutic agent in management of early-stage glottic laryngeal carcinoma.

Challenges and Considerations:

Despite the possible benefits, several challenges and reflections must be addressed before incorporating rosiglitazone into the standard treatment regimen for glottic laryngeal carcinoma. First and foremost, the safety profile of rosiglitazone in cancer patients needs thorough evaluation, as its long-term use may be associated with adverse effects, particularly in individuals already managing multiple health conditions.

Furthermore, the optimal dosage and duration of rosiglitazone treatment need clarification. Determining whether rosiglitazone should be administered as the monotherapy or in combination

through conventional treatments is essential for maximizing its efficacy. Rigorous clinical trials with well-defined protocols and endpoints are necessary to provide robust evidence supporting the use of rosiglitazone in the context of glottic laryngeal carcinoma.

The exploration of rosiglitazone as a potential adjunct therapy for early-stage glottic laryngeal carcinoma opens exciting avenues for enhansing the quality of life and prognosis of affected persons. While early research suggests promising anti-inflammatory and anti-tumor effects, rigorous clinical trials are needed to establish the safety, efficacy, and optimal treatment parameters. As the scientific community continues to unravel the complexities of cancer biology, repurposing existing drugs like rosiglitazone may offer innovative solutions in the quest for more effective and comprehensive cancer treatments.

CONCLUSION:

The impact of rosiglitazone on the quality of life and prediction of individuals with initial-stage glottic laryngeal carcinoma reveals promising avenues for further exploration. The potential benefits of incorporating rosiglitazone into treatment protocols suggest enhanced well-being and enhanced prognostic results for individuals. However, comprehensive research and medical tests are imperative to validate these findings, ensuring the safety and efficacy of rosiglitazone in the specific context of glottic laryngeal carcinoma. As medical science evolves, continued investigation into the nuanced effects of rosiglitazone may contribute valuable insights, potentially reshaping therapeutic strategies and positively influencing the overall management of this particular cancer.

REFERENCES:

Tables

Table 1: The pronunciation function in two groups before and after surgery

Groups	Fundamental frequency perturbation (× 10^9/L)		Amplitude perturbation (%)		Harmonic-to-noise ratio (dB)	
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group (n = 35)	2.42 ± 0.13	1.14± 1.08	5.68 ± 0.45	5.03 ± 0.36	19.48 ± 2.66	23.93 ± 3.05
Control group (n = 35)	1.45 ± 0.14	2.32 ± 1.13	5.66 ± 0.45	5.32 ± 0.41	19.52 ± 2.67	21.04 ± 2.86
T	0.866	7.098	0.167	2.783	1.088	4.498
P	0.392	< 0.002	0.868	0.009	1.932	0.002

Table 2: Adverse reactions in two groups

Groups	Infection	Swallowing dysfunction	Pharyngeal leakage	Nausea and vomiting	Liver and kidney damage	Adverse reaction rate (%)
Observation group	1 (1.01)	2 (3.87)	2 (2.87)	3 (6.74)	1 (1.01)	12.45
Control group	2 (3.87)	4 (8.59)	3 (6.74)	6 (15.31)	2 (3.87)	32.34